Clinical Trial Update: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study of PRGN-3007 UltraCAR-T cells in patients with advanced hematologic and solid tumors has completed enrollment, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Triple-negative Breast Cancer

Drugs mentioned

• PRGN-3007 UltraCAR-T Cells (PRGN-3007 UltraCAR-T)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Status: COMPLETED